Risk-targeted lung cancer screening a cost-effectiveness analysis

Annals of Internal Medicine

Volumn 168, Issue 3, 2018, Pages 161-169

  Kumar, Vaibhav ^a   Cohen, Joshua T ^a   Van Klaveren, David ^b   Soeteman, Djøra I ^c   Wong, John B ^a   Neumann, Peter J ^a   Kent, David M ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; EMPHYSEMA; FAMILY HISTORY; FEMALE; FIRST-DEGREE RELATIVE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; LIFE EXPECTANCY; LOW DOSE COMPUTED TOMOGRAPHY; LOW RISK POPULATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICARE; MIDDLE AGED; MORTALITY RISK; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; SMOKING; SMOKING CESSATION; THORAX RADIOGRAPHY; COST BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; ECONOMICS; EPIDEMIOLOGY; LUNG TUMOR; MASS SCREENING; MORTALITY; PATIENT SELECTION; RISK; UNITED STATES; X-RAY COMPUTED TOMOGRAPHY;

AGED; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LIFE EXPECTANCY; LUNG NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; PATIENT SELECTION; QUALITY-ADJUSTED LIFE YEARS; RADIOGRAPHY, THORACIC; RISK; SMOKERS; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 85042019450     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M17-1401     Document Type: Article

References (33)

1. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fager-strom RM, et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409. [PMID: 21714641] doi: 10.1056/NEJMoa1102873
2. Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160:330-8. [PMID: 24378917] doi:10 .7326/M13-2771
3. Wender R, Fontham ET, Barrera E Jr, Colditz GA, Church TR, Et-tinger DS, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013;63:107-17. [PMID: 23315954] doi: 10.3322/caac.21172
4. Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Car-diovasc Surg. 2012;144:33-8. [PMID: 22710039] doi:10.1016/j.jtcvs .2012.05.060
5. Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med. 2013;369:245-54. [PMID: 23863051] doi:10.1056/NEJMoa1301851
6. Katki HA, Kovalchik SA, Berg CD, Cheung LC, Chaturvedi AK. Development and validation of risk models to select ever-smokers for CT lung cancer screening. JAMA. 2016;315:2300-11. [PMID: 27179989] doi:10.1001/jama.2016.6255
7. Tammemägi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368:728-36. [PMID: 23425165] doi:10.1056/ NEJMoa1211776
8. Ten Haaf K, Jeon J, Tammemägi MC, Han SS, Kong CY, Plevritis SK, et al. Risk prediction models for selection of lung cancer screening candidates: a retrospective validation study. PLoS Med. 2017;14: e1002277. [PMID: 28376113] doi:10.1371/journal.pmed.1002277
9. van der Aalst CM, Ten Haaf K, de Koning HJ. Lung cancer screening: latest developments and unanswered questions. Lancet Respir Med. 2016;4:749-61. [PMID: 27599248] doi:10.1016 /S2213-2600(16)30200-4
10. Sanchez-Salcedo P, Wilson DO, de-Torres JP, Weissfeld JL, Berto J, Campo A, et al. Improving selection criteria for lung cancer screening. The potential role of emphysema. Am J Respir Crit Care Med. 2015;191:924-31. [PMID: 25668622] doi:10.1164/rccm .201410-1848OC
11. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26:2389-430. [PMID: 17031868]
12. de Wreede LC, Fiocco M, Putter H. The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models. Comput Methods Programs Biomed. 2010; 99:261-74 [PMID: 20227129] doi:10 1016/ cm b 2010 01 001
13. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371:796-7. [PMID: 25162885] doi:10.1056/ NEJMp1405158
14. Kim DD, Basu A, Dufy SQ, Zarkin GA. Appendix A. In: Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, eds. Cost-Effectiveness in Health and Medicine. 2nd ed. New York: Oxford Univ Pr; 2016:385-430.
15. Sturza J. A review and meta-analysis of utility values for lung cancer. Med Decis Making. 2010;30:685-93. [PMID: 20448248] doi: 10.1177/0272989X10369004
16. Centers for Medicare & Medicaid Services. Physician Fee Schedule look-up tool. Updated 3 August 2017. Accessed at www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PFSLookup on 15 July 2016.
17. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316:1093-103. [PMID: 27623463] doi:10.1001/jama.2016.12195
18. Kim JJ, Campos NG, Sy S, Burger EA, Cuzick J, Castle PE, et al; New Mexico HPV Pap Registry Steering Committee. Inefficiencies and high-value improvements in U.S. cervical cancer screening practice: a cost-effectiveness analysis. Ann Intern Med. 2015;163:589-97. [PMID: 26414147] doi:10.7326/M15-0420
19. Black WC, Gareen IF, Soneji SS, Sicks JD, Keeler EB, Aberle DR, et al; National Lung Screening Trial Research Team. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2014;371:1793-802. [PMID: 25372087] doi:10 .1056/NEJMoa1312547
20. Williams C, Lewsey JD, Mackay DF, Briggs AH. Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and Markov decision-analytic modeling. Med Decis Making. 2017;37:427-39. [PMID: 27698003] doi:10.1177/0272989X16670617
21. Williams C, Lewsey JD, Briggs AH, Mackay DF. Cost-effectiveness analysis in R using a multi-state modeling survival analysis framework: a tutorial. Med Decis Making. 2017;37:340-52. [PMID: 27281337] doi:10.1177/0272989X16651869
22. Goffin JR, Flanagan WM, Miller AB, Fitzgerald NR, Memon S, Wolfson MC, et al. Cost-effectiveness of lung cancer screening in Canada. JAMA Oncol. 2015;1:807-13. [PMID: 26226181] doi:10 .1001/jamaoncol.2015.2472
23. Kinsinger LS, Anderson C, Kim J, Larson M, Chan SH, King HA, et al. Implementation of lung cancer screening in the Veterans Health Administration. JAMA Intern Med. 2017;177:399-406. [PMID: 28135352] doi:10.1001/jamainternmed.2016.9022
24. Guessous I, Cornuz J. Why and how would we implement a lung cancer screening program? Public Health Rev. 2015;36:1-12. doi:10 .1186/s40985-015-0010-3
25. Goulart BH, Ramsey SD. Moving beyond the national lung screening trial: discussing strategies for implementation of lung cancer screening programs. Oncologist. 2013;18:941-6. [PMID: 23873718] doi:10.1634/theoncologist.2013-0007
26. Hayward RA, Kent DM, Vijan S, Hofer TP. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol. 2006;6:18. [PMID: 16613605]
27. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA. 2007;298:1209-12. [PMID: 17848656]
28. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010;11:85. [PMID: 20704705] doi:10.1186/ 1745-6215-11-85
29. Rothwell PM, Warlow CP. Prediction of benefit from carotid end-arterectomy in individual patients: a risk-modelling study. European Carotid Surgery Trialists' Collaborative Group. Lancet. 1999;353: 2105-10. [PMID: 10382694]
30. Kent DM, Nelson J, Dahabreh IJ, Rothwell PM, Altman DG, Hayward RA. Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials. Int J Epidemiol. 2016;45:2075-88. [PMID: 27375287] doi:10.1093/ije/dyw118
31. van Klaveren D, Wong JB, Kent DM, Steyerberg EW. Biases in individualized cost-effectiveness analysis: influence of choices in modeling short-term, trial-based, mortality risk reduction and post-trial life expectancy. Med Decis Making. 2017;37:770-8. [PMID: 28854143] doi:10.1177/0272989X17696994
32. Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, et al; PLCO Project Team. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011;306:1865-73. [PMID: 22031728] doi:10.1001/jama.2011.1591
33. Pope CA 3rd, Burnett RT, Turner MC, Cohen A, Krewski D, Jerrett M, et al. Lung cancer and cardiovascular disease mortality associated with ambient air pollution and cigarette smoke: shape of the exposure-response relationships. Environ Health Perspect. 2011;119:1616-21. [PMID: 21768054] doi:10 .1289/ehp.1103639